Stockreport

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, derisking the lead program ahead of pivotal studies. RXRX's $2.44bn market cap is justified by FA [Read more]